Uptown Research Institute

Running trials

• Recruiting

  A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

  NCT07592689· Phase 3· Source

• Recruiting

  A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

  NCT07615426· Phase 1· Source

• Recruiting

  A Study to Evaluate the Effect of KarXT on Urological Safety

  NCT07221877· Phase 4· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

  NCT07061288· Phase 1· Source

• Enrolling by invitation

  Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

  NCT06605105· Phase 3· Source

• Active, not recruiting

  A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

  NCT06894212· Phase 3· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Schizophrenia3 recruiting
• Depression2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

  NCT07191483· Phase 2· Source

• Completed

  "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

  NCT06564818· Phase 3· Source

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Source

• Terminated

  BHV-7000 Open-Label Extension Bipolar Mania Study

  NCT06423794· Phase 2· Source

• Completed

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· Phase 2· Source

• Completed

  BHV-7000 Acute Treatment of Bipolar Mania

  NCT06419582· Phase 2/3· Source

• Completed

  Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

  NCT06179108· Phase 2· Source

• Completed

  Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

  NCT05779241· Phase 3· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Source